Singular Genomics Systems, Inc. (NASDAQ:OMIC - Get Free Report) CEO Andrew Spaventa sold 800 shares of Singular Genomics Systems stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $19.89, for a total value of $15,912.00. Following the completion of the sale, the chief executive officer now owns 1,432 shares of the company's stock, valued at $28,482.48. The trade was a 35.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Andrew Spaventa also recently made the following trade(s):
- On Monday, December 16th, Andrew Spaventa sold 180 shares of Singular Genomics Systems stock. The stock was sold at an average price of $20.16, for a total value of $3,628.80.
Singular Genomics Systems Stock Performance
Shares of Singular Genomics Systems stock traded up $0.08 on Tuesday, reaching $20.04. 16,037 shares of the stock were exchanged, compared to its average volume of 8,844. The company has a quick ratio of 6.67, a current ratio of 7.37 and a debt-to-equity ratio of 0.04. Singular Genomics Systems, Inc. has a twelve month low of $5.34 and a twelve month high of $23.41. The firm has a market capitalization of $50.89 million, a price-to-earnings ratio of -0.57 and a beta of 1.83. The business has a 50 day moving average price of $19.77 and a two-hundred day moving average price of $16.12.
Institutional Investors Weigh In On Singular Genomics Systems
A hedge fund recently raised its stake in Singular Genomics Systems stock. Geode Capital Management LLC raised its stake in Singular Genomics Systems, Inc. (NASDAQ:OMIC - Free Report) by 7.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 17,962 shares of the company's stock after acquiring an additional 1,193 shares during the quarter. Geode Capital Management LLC owned approximately 0.72% of Singular Genomics Systems worth $282,000 at the end of the most recent reporting period. 65.80% of the stock is currently owned by institutional investors and hedge funds.
About Singular Genomics Systems
(
Get Free Report)
Singular Genomics Systems, Inc, a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue.
Featured Articles
Before you consider Singular Genomics Systems, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Singular Genomics Systems wasn't on the list.
While Singular Genomics Systems currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
